Back to search results

Study of Mosliciguat for Pulmonary Hypertension with Interstitial Lung Disease

This study is looking at the safety and how well inhaled mosliciguat works when given along with inhaled treprostinil (another medication for pulmonary hypertension) to people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD is a condition where high blood pressure in the lungs is linked to lung scarring. We want to see if mosliciguat causes any side effects or serious problems. You could be eligible if you are between 18 and 85 years old, are already taking inhaled treprostinil, and have a confirmed diagnosis of ILD. This study is open-label, meaning both you and the study team will know which treatment you are receiving. We plan to enroll 20 participants.

Study design
This is a Phase 2, open-label study, meaning both you and the study team will know which treatment you are receiving. It involves about 20 participants.
What's involved
You would receive inhaled mosliciguat for at least 16 weeks, with the option to continue in an extension period beyond 16 weeks.
Compensation
Not stated in the trial record.
Follow-up
The study will measure side effects and other issues at Baseline and Week 16.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Recruiting
PHASE2Ages 18–85InterventionalTreatment
Pulmovant, Inc.
~20 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:inhaled mosliciguatDry Powder Inhaler

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation
Measured over Baseline, Week 16

Conditions

Pulmonary Hypertension
Interstitial Lung Disease (ILD)
Lung Diseases
Vascular Diseases
Cardiovascular Diseases
Fibrosis

Explore related trials

Interstitial Lung DiseasePulmonary Hypertension

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Ubaldo Martin, MD · STUDY_DIRECTOR · Pulmovant, Inc.

Who to contact

Pulmovant
[email protected]
+1-919-462-1310
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants willing and able to provide informed consent
Participants on inhaled treprostinil
Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
Ability to perform 6MWD ≥100 meters.

Exclusion

Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Exacerbation of underlying lung disease within 28 days prior to randomization.
Initiation of pulmonary rehabilitation within 28 days prior to randomization.
Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.

What this trial measures

  • Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuationBaseline, Week 16